Advanced technology for an implantability advantage

Cinch® Implant System deflects the stent posts inward and holds them in place during implant. This allows visibility of the sewing ring in tight spaces (i.e., small incisions, tight roots), which is not always possible with other tissue valve substitutes when working with difficult patient anatomies. Also, with mitral valve replacement, the patented Cinch system aids in the prevention of suture looping around stent posts.

Flexible acetal homopolymer stent offers stent memory. This 3rd generation stent offers more forgiveness than 2nd generation copolymer stents. Furthermore, this flexible stent design with memory is a more ideal option for navigating through tight spaces than the metal stent designs seen on pericardial valves.

Physiologic Fixation™ process provides you with a valve with a view. This unique process preserves the leaflets in their physiologic state, which serves two purposes: aids visualization of pledget placement; and enables viewing of valve seating during implantation. Also, the Physiologic Fixation process is designed to improve long-term durability and mitigate biomechanical failure by maintaining the extensibility and collagen crimp characteristics of the valve leaflets.

Growing evidence of proven clinical performance

In June 2009, three mid-term studies for the Mosaic valve were presented at the 5th Biennial Meeting of the Society for Heart Valve Disease^1-3. In summary:

14-year results¹ Our midterm results demonstrate clinical safety and excellent performance of the MOSAIC bioprosthesis.

12-year results²  The overall performance of the Medtronic Mosaic porcine bioprosthesis, at 12 years is satisfactory, comparable to other bioprostheses. The freedom from SVD diagnosed by explant reoperation is most satisfactory for AVR >60 years & MVR >70 years. Overall actuarial freedom from SVD by explant reoperation seems to be particularly good in patients having MVR.

10-year results³ The 10-year follow up of the Mosaic bioprosthesis in aortic position demonstrates low valve related complications and incidence of structural deterioration. The absence of central valve leakage and the stable low valve gradients contributed to a significant reduction in left ventricular mass.

See how durability of the Mosaic valve compares to other stented bioprosthetic valves at 7 years, 10 years and 12 years.

Learn more about AOA^® tissue treatment, durability and survival results for the Mosaic valve.